Trials

BORTEM-17: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide a phase IB/II study

Cancer type: Glioblastoma

Phase: I/II

Principal Investigator: Golpen Dorota

Country: NO

Keywords: Norway, Bergen, Glioblastoma, Bortezomib and Telozolomide

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03643549?cond=Glioblastoma&cntry=NO&rank=1